Skip to search formSkip to main contentSkip to account menu

poly(gamma-glutamylglutamine)paclitaxel

Known as: PGG-PTX 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

PaclitaxelProteins
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.
2015
2015
Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic…
Immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies are emerging as an important therapeutic modality in… 
2015
2015
A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
TPS787 Background: Imprime PGG (Imprime) is a novel immune modulator (complex carbohydrate biologic), which harnesses innate… 
2015
2015
Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype
Imprime PGG (Imprime) in combination with anti-VEGF monoclonal antibody, bevacizumab has shown promising clinical efficacy in… 
Review
2015
Review
2015
Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with…
3070 Background: Recently, we reported numeric improvements in objective tumor response (OTR) and overall survival (16.1 vs 11.6… 
2013
2013
Abstract B65: Immune cell priming and potentiation of anti-tumor effects by Imprime PGG®
Biothera is developing Imprime PGG® (Imprime PGG) for cancer that is synergistic with multiple anti-tumor monoclonal antibodies… 
2012
2012
Abstract A19: Imprime PGG®, a soluble β-1,3/1,6 immunomodulatory glucan, induces enhanced antitumor activity in an in vivo pancreatic tumor model when combined with cetuximab and gemcitabine.
Advances in targeted therapeutics, such as the anti-Epidermal Growth Factor Receptor (EGFR) MAb, cetuximab (Erbitux®), have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)